Endocyte, Inc. Common Stock
ECYT
ECYT was delisted on the 20th of December, 2018.
101 hedge funds and large institutions have $126M invested in Endocyte, Inc. Common Stock in 2014 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 40 increasing their positions, 28 reducing their positions, and 40 closing their positions.
43% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 28
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
17% less funds holding
Funds holding: 121 → 101 (-20)
50% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 40
66% less call options, than puts
Call options by funds: $4.89M | Put options by funds: $14.2M
76% less capital invested
Capital invested by funds: $535M → $126M (-$409M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
+$9.78M |
| 2 |
PAAMCP
Pacific Alternative Asset Management Company (PAAMCO)
Irvine,
California
|
+$5.23M |
| 3 |
ARTA
A.R.T. Advisors
New York
|
+$3.21M |
| 4 |
GC
Guggenheim Capital
Chicago,
Illinois
|
+$2.37M |
| 5 |
Renaissance Technologies
New York
|
+$2.37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$16M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$14.8M |
| 3 |
RIM
RS Investment Management
San Francisco,
California
|
-$11.2M |
| 4 |
UBS AM
Chicago,
Illinois
|
-$10.4M |
| 5 |
PA
Perceptive Advisors
New York
|
-$10.4M |
ECYT Hedge Fund Activity: Q2 2014 in Review
101 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in Endocyte, Inc. Common Stock (ECYT) for Q2 2014, worth a combined $126M — down 76% from $535M a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of ECYT and 20 opened new positions — a net loss of 20 holders — while 28 trimmed existing stakes and 40 added.
The largest buyer was Bogle Investment Management, opening a new position worth an estimated $9.78M. The largest seller was Oracle Investment Management, exiting entirely with an estimated $16M sold.
- 101 institutional investors held Endocyte, Inc. Common Stock (ECYT) as of Q2 2014, down from 121 in Q1 2014.
- Funds reported $126M of Endocyte, Inc. Common Stock stock for Q2 2014, down 76% quarter-over-quarter.
- 20 funds opened new Endocyte, Inc. Common Stock positions in Q2 2014 and 40 closed out, a net change of -20 holders.
- The largest Endocyte, Inc. Common Stock buyer in Q2 2014 was Bogle Investment Management, an estimated $9.78M added.
- The largest Endocyte, Inc. Common Stock seller in Q2 2014 was Oracle Investment Management, an estimated $16M sold.
Based on aggregated 13F filings for Q2 2014.